C-peptide microheterogeneity in type 2 diabetes populations. - Wikidata - wikimedia - TriplyDB

C-peptide microheterogeneity in type 2 diabetes populations.

C-peptide microheterogeneity in type 2 diabetes populations.

http://www.wikidata.org/entity/Q33764455

about

Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: potential applications to cardiovascular disease and diabetes Building multidimensional biomarker views of type 2 diabetes on the basis of protein microheterogeneity Mass spectrometric immunoassay revisited Peptide immunoaffinity enrichment coupled with mass spectrometry for peptide and protein quantification.Mass spectrometric immunoassay of intact insulin and related variants for population proteomics studies.Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum Mass Spectrometric Immunoassays in Characterization of Clinically Significant Proteoforms.

P2860

Q33643266-357A11C7-1C95-4488-B277-3B245350B9A1 Q33845667-B80427D2-EB38-4F1D-96DF-987A4D6DDA61 Q34033095-49FDDCFD-0B71-41EE-944B-13333EB222A7 Q35264312-BD60412D-1CD9-434F-AEB6-1A9BACA73220 Q37004146-E206F126-7FE5-4B54-942E-F982859F1116 Q37187946-7C421792-D859-45A8-BBC1-39AE14F336A3 Q37566426-0EBA8D5E-C686-4AA4-B91A-2A6FCB9746D9

P2860

C-peptide microheterogeneity in type 2 diabetes populations.

http://www.wikidata.org/entity/Q33764455

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

C-peptide microheterogeneity in type 2 diabetes populations.

@ast

C-peptide microheterogeneity in type 2 diabetes populations.

@en

type

label

C-peptide microheterogeneity in type 2 diabetes populations.

@ast

C-peptide microheterogeneity in type 2 diabetes populations.

@en

prefLabel

C-peptide microheterogeneity in type 2 diabetes populations.

@ast

C-peptide microheterogeneity in type 2 diabetes populations.

@en

P1433

Q33764455-13883862-348A-4B77-9753-66615557E499

P1476

Q33764455-769112EE-6760-4289-AA2E-E23C721467A7

P2093

Q33764455-147DD2D2-B981-4A21-ADB4-B89CAB00E403

Q33764455-5237A941-AB7D-4C6D-829C-D830ABB885B6

Q33764455-629E2931-086C-4612-AC7E-685E0CEC5DB7

Q33764455-62AD839D-A591-4DCD-857D-740EA42BB2E8

P2860

Q33764455-0BF997DA-E67C-4AC7-99A1-5338522E5384

Q33764455-11036570-CADC-4C5A-B336-9FC17CA8CDF7

Q33764455-12897613-DBF1-4A9C-AE43-6199AC87BA05

Q33764455-14189C3D-6036-4249-A045-2CD518A9B80F

Q33764455-17161B3D-4C97-405B-8434-4D9D5A4275C3

Q33764455-1A7C6FF7-3F37-449C-8E37-4FD2B24CDF20

Q33764455-1C4A2D8D-B109-479A-8853-F827D681DD1A

Q33764455-1E816B6E-B11F-45F6-A405-9F81CAA70941

Q33764455-344482BB-5DE7-4F4E-B6E8-16704E2838CD

Q33764455-41DFF790-E6AD-40EF-AB7F-1933F609315E

P304

Q33764455-8C837124-0EF7-4DFB-9C42-9CDF119989A0

P31

Q33764455-215C111B-0C9F-4095-A5F0-544E687307CC

P356

Q33764455-D49C72D3-562A-4AFD-9BCD-FBBC90FBBC03

P433

Q33764455-D2B18404-4258-4812-9A3E-8E59E3593F30

P478

Q33764455-816B488B-780B-4429-822D-5771AE49D1E9

P577

Q33764455-14A2BB2A-BB0B-4864-AF1C-FD3599218A9D

P698

Q33764455-B7C02DE2-1862-4AAD-88F6-E5E844A68949

P921

Q33764455-D2BB14F9-30E9-4EB7-87BE-84CB0120D16B

P932

Q33764455-F2D61A5C-A565-4171-AC4F-F531F6990E6C

P356

P1433

Proteomics - Clinical Applications

P1476

C-peptide microheterogeneity in type 2 diabetes populations.

@en

P2093

Chad R Borges

http://www.w3.org/2001/XMLSchema#string

Jason W Jarvis

http://www.w3.org/2001/XMLSchema#string

Paul E Oran

http://www.w3.org/2001/XMLSchema#string

Randall W Nelson

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of EDTA and Sodium Citrate on hormone measurements by fluorometric (FIA) and immunofluorometric (IFMA) methods

Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog

Novel mass spectrometric immunoassays for the rapid structural characterization of plasma apolipoproteins.

Mass spectrometric immunoassay.

Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure.

Insulin assays and reference values.

C-peptide: much more than a byproduct of insulin biosynthesis.

Glucagon-like peptide 1(GLP-1) in biology and pathology.

Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients.

Molecular effects of proinsulin C-peptide.

P304

106-111

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PRCA.200800249

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21137020

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

3761384

http://www.w3.org/2001/XMLSchema#string